Sie sind auf Seite 1von 2

ALPCO Launches FDA Class I Exempt STELLUX® Glucagon ELISA

ALPCO announces launch of its new highly specific FDA Class I Exempt STELLUX® Chemi
Glucagon ELISA.

Salem, NH, October 23, 2018 --(PR.com)-- ALPCO, a leading producer of research and clinical
immunoassays, has announced the launch of its FDA Class I Exempt STELLUX® Chemi Glucagon
ELISA. The chemiluminescence ELISA features increased specificity and a broad range to accurately
quantify glucagon levels between 0.86 and 143.7 pmol/L (3-500 pg/mL).

Glucagon measurements are used in the diagnosis and treatment of patients with various disorders of
carbohydrate metabolism, including diabetes mellitus, hypoglycemia, and hyperglycemia. Furthermore,
researchers are interested in investigating the possible connections between glucagon, pancreatic alpha
cell function, and the pathophysiology of diseases such as diabetes mellitus. However, the sequence of
glucagon makes it a difficult biomarker to specifically measure, thus creating obstacles for diabetes
researchers.

“Our customers were experiencing challenges in confidently quantifying glucagon levels without
cross-reactivity to oxyntomodulin, a proglucagon peptide containing the glucagon sequence known for
interfering with glucagon assays,” explains ALPCO's president, Sean Conley. “We designed our
STELLUX® Chemi Glucagon ELISA to address this need and provide a more specific multifunctional
tool for both diagnostic and research laboratories. We are confident this assay will empower users to
further their research and improve clinical outcomes."

The STELLUX® Chemi Glucagon ELISA is highly specific with 100% cross-reactivity to glucagon, and
does not cross-react with other proglucagon peptides such as oxyntomodulin, glicentin and the incretins
glucagon-like peptide-1 and gastric inhibitory polypeptide. The broad range and increased specificity of
the assay allows laboratories to effectively quantify both fasted and fed levels of glucagon in mouse, rat,
and human plasma samples. Additionally, the assay is validated for use with cell culture and is a robust
tool for studying perifusion models.

Visit alpco.com to learn more about the STELLUX® Glucagon ELISA.

About ALPCO
American Laboratory Products Company (ALPCO) was founded in 1991 as an importer and distributor of
immunoassay-based products for the North American life science markets. The company has since grown
into a premier channel representing over 60 collaborating partners from around the globe. Today, ALPCO
offers a wide range of testing solutions, providing scientists and healthcare professionals with vital tools
for advancing research and improving quality of care.

Page 1/2
PR.com Press Release Distribution Terms of Use
Contact Information:
ALPCO
Christiann Cailouette
1-800-592-5726
Contact via Email
www.alpco.com

Online Version of Press Release:


You can read the online version of this press release at: https://www.pr.com/press-release/768159

News Image:

Page 2/2
PR.com Press Release Distribution Terms of Use